Literature DB >> 24928315

Neuroprotective effects of C3 exoenzyme in excitotoxic retinopathy.

Yun Wang1, Ying Wang2, Qiaona Yang3, Liheng Guo3, Yan Yin3, Ning Fan1, Xiaomin Zhou3, Su-Ping Cai1, Paul L Kaufman4, Xuyang Liu5.   

Abstract

The purpose of this study is to evaluate the neuroprotective effects of C3 exoenzyme (C3) on N-methyl-d-aspartate (NMDA)-induced retinopathy in rats. C3 was expressed in Escherichia. coli and purified by affinity chromatography. Immunofluorescence was performed in NIH 3T3 cells treated with C3 to verify the cellular uptake of the protein. NMDA was injected intravitreally into rat eyes with or without C3. At various time points after injection, eyes were enucleated. Hematoxylin/eosin staining was performed on retina cross-sections for morphological analysis. Survival and apoptosis of cells in the ganglion cell layer (GCL) were assessed by cresyl violet staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) on retina flat-mounts. RhoA levels in retina cells were evaluated by Western blot to detect C3 uptake in vivo. The cellular uptake of C3 was verified by immunofluorescence. Damage including a decrease in inner plexiform layer (IPL) thickness and reduction of cell density in the GCL, corresponding to apoptosis of neurons, was induced by intravitreal injection of NMDA. Protection against this damage was observed following co-injection of C3 and NMDA. RhoA ADP-ribosylation induced by C3 was confirmed by Western blot. Our results suggest that C3 exerts neuroprotective effects against excitotoxic damage induced by NMDA.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C3; excitotoxicity; glaucoma; neuroprotection

Mesh:

Substances:

Year:  2014        PMID: 24928315      PMCID: PMC4251735          DOI: 10.1016/j.exer.2014.05.018

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  26 in total

Review 1.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development.

Authors: 
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

2.  Switching mature retinal ganglion cells to a robust growth state in vivo: gene expression and synergy with RhoA inactivation.

Authors:  Dietmar Fischer; Victoria Petkova; Solon Thanos; Larry I Benowitz
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

3.  The effect of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes.

Authors:  Xuyang Liu; Yujie Hu; Mark S Filla; B'Ann T Gabelt; Donna M Peters; Curtis R Brandt; Paul L Kaufman
Journal:  Mol Vis       Date:  2005-12-13       Impact factor: 2.367

Review 4.  C3 exoenzymes, novel insights into structure and action of Rho-ADP-ribosylating toxins.

Authors:  Martin Vogelsgesang; Alexander Pautsch; Klaus Aktories
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-12-05       Impact factor: 3.000

5.  Interactive effects of C3, cyclic AMP and ciliary neurotrophic factor on adult retinal ganglion cell survival and axonal regeneration.

Authors:  Ying Hu; Qi Cui; Alan R Harvey
Journal:  Mol Cell Neurosci       Date:  2006-11-27       Impact factor: 4.314

6.  Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina.

Authors:  Yuka Kitaoka; Yasushi Kitaoka; Toshio Kumai; Tim T Lam; Kohei Kuribayashi; Kazuyuki Isenoumi; Yasunari Munemasa; Masamitsu Motoki; Shinichi Kobayashi; Satoki Ueno
Journal:  Brain Res       Date:  2004-08-20       Impact factor: 3.252

7.  RhoA controls myoblast survival by inducing the phosphatidylinositol 3-kinase-Akt signaling pathway.

Authors:  Mickol Reuveny; Hanna Heller; Eyal Bengal
Journal:  FEBS Lett       Date:  2004-07-02       Impact factor: 4.124

8.  Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death.

Authors:  Maria M Semenova; Anu M J Mäki-Hokkonen; Jiong Cao; Vladislav Komarovski; K Marjut Forsberg; Milla Koistinaho; Eleanor T Coffey; Michael J Courtney
Journal:  Nat Neurosci       Date:  2007-03-18       Impact factor: 24.884

9.  Rho signaling pathway targeted to promote spinal cord repair.

Authors:  Pauline Dergham; Benjamin Ellezam; Charles Essagian; Hovsep Avedissian; William D Lubell; Lisa McKerracher
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

10.  Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system.

Authors:  Catherine I Dubreuil; Matthew J Winton; Lisa McKerracher
Journal:  J Cell Biol       Date:  2003-07-14       Impact factor: 10.539

View more
  5 in total

1.  C3 exoenzyme impairs cell proliferation and apoptosis by altering the activity of transcription factors.

Authors:  Leonie von Elsner; Sandra Hagemann; Ingo Just; Astrid Rohrbeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-06-28       Impact factor: 3.000

2.  scAAV2-Mediated C3 Transferase Gene Therapy in a Rat Model with Retinal Ischemia/Reperfusion Injuries.

Authors:  Junkai Tan; Xiaoguang Zhang; Danli Li; Guo Liu; Yun Wang; Daren Zhang; Xizhen Wang; Wenhong Tian; Xiaoyan Dong; Liang Zhou; Xianjun Zhu; Xuyang Liu; Ning Fan
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-25       Impact factor: 6.698

Review 3.  Use of Gene Therapy in Retinal Ganglion Cell Neuroprotection: Current Concepts and Future Directions.

Authors:  Jess Rhee; Kendrick Co Shih
Journal:  Biomolecules       Date:  2021-04-15

4.  Targeting Polyamine Oxidase to Prevent Excitotoxicity-Induced Retinal Neurodegeneration.

Authors:  Prahalathan Pichavaram; Chithra Devi Palani; Chintan Patel; Zhimin Xu; Esraa Shosha; Abdelrahman Y Fouda; Ruth B Caldwell; Subhadra Priya Narayanan
Journal:  Front Neurosci       Date:  2019-01-10       Impact factor: 4.677

5.  C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey.

Authors:  Junkai Tan; Xizhen Wang; Suping Cai; Fen He; Daren Zhang; Dongkan Li; Xianjun Zhu; Liang Zhou; Ning Fan; Xuyang Liu
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-29       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.